Technology and Science19 September, 20263 min read
“Mammogram We Can Afford” Funding Gap Leaves “Cancer We Can’t” Out of Reach
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Funding gaps block access to affordable mammograms and timely cancer treatment. Markets and philanthropic investments are urged to fund equitable cancer care strategies.
6 outlets told this the same way.
Early detection vs access
A new argument in the cancer-financing debate centers on whether the “Mammogram We Can Afford” can arrive in time for the “Cancer We Can’t,” as the piece says funding remains a “critical barrier between when and how cancer is treated and who can access care.” The article says that in 2025 “more than 316,000 American women were expected to be diagnosed with breast cancer,” and it links survival to stage, stating that women diagnosed while cancer is localized see survival rates “near 100%.”
“Funding is a critical barrier between when and how cancer is treated and who can access care.”
It also points to cervical cancer as “one of the most preventable and detectable cancers,” saying it “kills more than 4,000 women annually,” and it contrasts that toll with the Centers for Disease Control and Prevention’s screening reach of “more than 6.5 million low-income and underinsured women” through a program that “operates on roughly $200 million a year.” The piece frames the financing problem as a market failure, saying “the benefits of screening and early diagnosis are spread across patients, employers, insurers, health systems, and governments,” while “Capital, therefore, flows more readily toward interventions with immediate revenue streams.”
Physicians: the hardest part
On KevinMD.com, a page described as a maintained record of physician-authored essays and podcast transcripts says the hardest part of cancer care, “in the words of the physicians who provide it, is not the treatment but the conversation.”
The same page says the site is “founded in 2004 byKevin Pho, MD,” and it describes how the record has grown to “1,255 essays and podcast transcripts” published between “May 2004 and September 2026” by “414 named contributors.”
It also quotes Amy Tuteur, MD, writing in November 2009 that the American Cancer Society “has acknowledged that cancer screening has been oversold,” and that screening with the PSA test “saves no more lives than screening with a prostate exam.”
The page then cites Ryan Polselli, MD, a breast imaging radiologist, writing in June 2026 that the U.S. Preventive Services Task Force “now recommends biennial screening mammography for women ages 40 to 74,” while quality measures ask only whether a woman had a mammogram in a roughly two-year window.
Costs, coordination, and biosimilars
In a separate account of cancer costs, a retired teacher named Ms. Farhadi says her main drug’s price rose from “under one million tomans per cycle to tens of millions,” and she was at one point asked to pay the entire “90 million tomans.”
She describes the timing of the burden as tied to treatment repetition “every 20 days,” and she says she ultimately obtained her last dose for about “20 million tomans,” while also paying about “6.5 million tomans” for injections.
In Humana’s research, specialty pharmacy care coordination is linked to fewer acute-care events, with the study described as finding an “11.7% reduction in hospitalizations” and a “2.7% drop in emergency department visits.”
The Cancer Letter also points to a UCLA Health Jonsson Comprehensive Cancer Center study, saying “lower-cost versions known as biosimilars” are associated with “lower costs for both insurers and patients,” even as it notes that high-cost biologic drugs can add to the “financial burden of cancer care.”